Fact Check: Moderna began clinical trials of COVID vaccine in 2020, not 2017
Data on mRNA vaccines sent by Moderna to European regulators before the COVID-19 outbreak included early tests of the mRNA ...
Moderna Shares Plunge After Predicting Steep 2025 Sales Decline
The company's newer product, an RSV ( respiratory syncytial virus) vaccine, has also underperformed, contributing "minimal sales" in 2024. Analysts' concerns were heightened by the company's revised ...
pharmaphorum10d
Moderna follows Pfizer in asking FDA for second COVID booster okay
Moderna has asked the FDA for emergency use authorisation for a fourth dose of its mRNA COVID-19 vaccine SpikeVax ... Pfizer's application was from an open-label study in Israel involving ...
Newsday29d
Moderna surprises the Street by predicting a bigger-than-expected sales drop
Moderna pulled in most of its revenue last year from its COVID-19 vaccine, Spikevax, which brought in more than $3 billion in sales. Regulators also approved a Moderna vaccine for RSV, or ...
Hosted on MSN17d
Moderna Retains Retail Support With European COVID-19 Vaccine Tender Win, Stock Hits 2-Week High
Shares of Moderna Inc. climbed nearly 1% on Friday, reaching levels last seen on Jan. 10, as retail sentiment turned increasingly positive following the company’s announcement of a new vaccine tender ...
FiercePharma6d
Moderna picks Merck KGaA, Roivant alum as marketing chief
As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...
Miami Herald29d
Moderna Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
This includes more than $3.0 billion in Spikevax ... label extension study. The Company began generating registrational trial data in 2024. Methylmalonic acidemia (MMA) therapeutic: Moderna's ...